## AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently Amended) A method for treating a mammal infected with respiratory syncytial virus (RSV), which comprises administering to the mammal a therapeutically effective amount of one or more compounds of formula I:




Formula I

or pharmaceutically acceptable salts or derivatives thereof, wherein

A, together with the atoms to which it is attached, forms an optionally substituted pyridyl ring;

linker –B–C– is an optionally substituted linker of the formula $–CH_2(CH_2)_z–$, where z is 1 ~~or 2~~;

$R_1$ is optionally substituted aryl ~~or heterocyclyl~~;

$R_2$ is ~~selected from~~ $–C(O)R_3$ ~~and $–C(O)N(R_4)R_3$~~, where $R_3$ is selected from $–(CH_2)_m$ aryl and $–(CH_2)_m$ heterocyclyl; where m is 0 or 1; ~~and when $R_2$ is $–C(O)R_3$, $R_3$ is further selected from $–S–R_5$ and $–O–R_5$; m is 0-3; $R_4$ is hydrogen or $C_{1-6}$ alkyl;~~ and the ~~alkyl,~~ aryl and heterocyclyl groups are optionally substituted; and

X is O.

2-8. (Cancelled).

9. (Previously Presented) The method according to claim 1, wherein ring A is optionally substituted with one or more substituents independently selected from halo, $–NH_2$, $–NO_2$, $C_{1-6}$ alkyl, aryl and heterocyclyl, where the aryl and heterocyclyl groups are optionally substituted with halo, $C_{1-6}$ alkyl or halo substituted $C_{1-6}$ alkyl, and the optional substituents are further selected from an N-oxide of the pyridyl ring nitrogen and pyridinium salts thereof.

10. (Previously Presented) The method according to claim 9, wherein ring A is optionally substituted with a substituent selected from halo, alkyl, $C_6H_5$–, $CH_3$–$C_6H_4$–, $CF_3$–$C_6H_4$–, pyridyl and –$NO_2$, and the optional substituent is further selected from an N-oxide form of the ring nitrogen, and pyridinium salts thereof.

11. (Previously Presented) The method according to claim 1, wherein ring A is not substituted.

12. (Previously Presented) The method according to claim 1, wherein the compound of formula I is a compound of the formula IV




Formula IV

or an N-oxide or pharmaceutically acceptable salt or derivative thereof.

13. (Currently Amended) The method according to claim 1, wherein $R_2$ is ~~selected from~~ –C(O)$R_3$ ~~and –C(O)N($R_4$)$R_3$~~, where $R_3$ is selected from –$(CH_2)_m$ aryl and –$(CH_2)_m$ heterocyclyl~~, and when $R_2$ is –C(O)$R_3$, $R_3$ is further selected from –S–$R_5$ and –O–$R_5$; m is 0-3; $R_4$ is hydrogen or is $C_{1-6}$ alkyl~~; and the ~~alkyl,~~ aryl and heterocyclyl groups are optionally substituted with one or more substituents selected from $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, halo, halo–$C_{1-6}$ alkyl, $CF_3$, hydroxy, mercapto, nitro, cyano, $NH_2$, mono and di($C_{1-6}$ alkyl)amino, phenyl, benzyl and heterocyclyl.

14-15. (Cancelled).

16. (Previously Presented) The method according to claim 1, wherein $R_3$ is optionally substituted and is selected from phenyl, naphthyl, furyl, thienyl, pyrrolyl, *H*-pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, triazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, tetrazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyranyl, pyrazinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, triazinyl, 1*H*-thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl, indolyl, isoindolyl, benzofuranyl, benzothienyl,

benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, uridinyl, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzotriazinyl, naphthyridinyl and pteridinyl.

17. (Previously Presented) The method according to claim 16, wherein $R_3$ is optionally substituted with one or more substituents selected from $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, halo, halo–$C_{1-6}$ alkyl, $CF_3$, hydroxy, mercapto, nitro, cyano, $NH_2$, mono and di($C_{1-6}$ alkyl) amino, phenyl, benzyl and heterocyclyl.

18-22. (Cancelled).

23. (Previously Presented) The method according to claim 1, wherein linker –B–C– is not substituted.

24-25. (Cancelled).

26. (Currently Amended) The method according to claim 1, wherein $R_1$ represents phenyl, ~~thienyl, pyrrolyl, pyridyl, or pyridyl, each~~ optionally substituted with halo, hydroxy, nitro, -NR'R", $C_{1-12}$ alkyl, phenyl or –O–$R_a$, where R' and R" are independently selected from hydrogen, lower alkyl and –C(O)R, where R is $C_{1-6}$ alkyl, phenyl or heterocyclyl; $R_a$ is –$C_{1-12}$ alkyl, –$C_{3-7}$ cycloalkyl, –$C_{1-12}$ alkyl$C_{3-7}$ cycloalkyl, phenyl or –$C_{1-12}$ alkylphenyl; and the $C_{1-12}$ alkyl, phenyl or $R_a$ group is optionally substituted with halo, –CN, –$NR^{10}R^{11}$, –$CO_2R^{12}$ or –$CONR^{10}R^{11}$, where $R^{10}$, $R^{11}$ and $R^{12}$ are independently selected from hydrogen and lower alkyl.

27. (Previous Presented) The method according to claim 1, wherein $R_1$ is phenyl optionally substituted with a substituent selected from halo, –$C_{1-6}$ alkyl, –$C_{1-6}$ alkylhalo, –$C_{1-6}$ alkylCN, –$OC_{1-6}$ alkyl, –$OC_{1-6}$ alkylhalo, –$OC_{1-6}$ alkyl$CO_2NH_2$, –$OC_{1-6}$ alkylCN, –$OC_{1-6}$ alkyl$C_{3-7}$ cycloalkyl, –$OC_{1-6}$ alkyl$C_6H_5$, –$OC_{1-6}$ alkyl$OCH_3$, –$OC_6H_5$, –$OC_6H_4$halo, –$CF_3$, –$OCF_3$, –NR'R", –$CO_2H$, –$CO_2C_{1-6}$ alkyl, –$NO_2$, –OH, –$C_6H_5$, –$C_6H_4C_{1-6}$ alkyl, –$C_6H_4$halo and –$OC(O)C_{1-6}$ alkyl; where R' and R" are independently selected from hydrogen, –$C(O)C_{1-6}$ alkyl, –$C(O)C_6H_5$, –C(O)CH=CH$CO_2H$, –$C(O)C_{1-6}$ alkyl$CO_2H$, –$C(O)C_{1-6}$ alkyl$CO_2CH_3$, –$C(O)C_{1-6}$ alkyl$C_6H_5$, –$C(O)C_{1-6}$ alkyl$C_6H_4CH_3$, –$C(O)C_{1-6}$ alkyl$C_6H_4OCH_3$ and –$C(O)C_{1-6}$ alkyl$C_6H_4$halo.

28. (Currently Amended) The method according to claim 1, wherein $R_1$ is phenyl substituted with halo, $C_{1-6}$ alkyl, –$OC_{1-6}$ alkyl, –$OC_{1-6}$ alkylhalo, –$OC_{1-6}$ alkyl$CO_2NH_2$, –$OC_{1-6}$ alkylCN, –$OC_{1-6}$ alkyl$C_{3-7}$ cycloalkyl, –$OC_{1-6}$ alkyl$C_6H_5$ or –$OC_{1-6}$ alkyl$OCH_3$.

29. (Previously Presented) The method according to claim 1, wherein $R_1$ is 4-chlorophenyl.

30. (Previously Presented) A method for the treatment of infections involving RSV by the inhibition of virus fusion processes, comprising administering a therapeutically effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt or derivative thereof, to a patient in need of treatment.

31-36. (Cancelled).

37. (Previously Presented) The method of claim 1 for the treatment of human RSV.

38. (Currently Amended) A compound of formula I




Formula I

or a salt or pharmaceutically acceptable derivative thereof, wherein:

A, together with the atoms to which it is attached, represents an optionally substituted pyridyl;

linker –B-C– is an optionally substituted linker of the formula $–CH_2(CH_2)_z–$, where z is 1[[-4]];

$R_1$ is ~~selected from $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, $C_{2-12}$ alkynyl, $(CH_2)_nC_{3-7}$ cycloalkyl, $(CH_2)_nC_{4-7}$ cycloalkenyl, $(CH_2)_n$~~ aryl, ~~$(CH_2)_n$ aryl$C_{1-12}$ alkyl, $(CH_2)_n$ aryl$C_{2-12}$ alkenyl, $(CH_2)_n$ aryl$C_{2-12}$ alkynyl and $(CH_2)_n$ heterocyclyl; n is 0-6; and the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are~~ optionally substituted;

$R_2$ is –C(O)$R_3$ ~~selected from $CH_2R_3$, $C(Y)R_3$, $C(Y)OR_3$, $C(Y)N(R_4)R_3$ and $S(O)_wR_5$;~~ where $R_3$ is selected from ~~$(CH_2)_mC_{3-7}$ cycloalkyl, $(CH_2)_mC_{4-7}$ cycloalkenyl,~~ $–(CH_2)_m$ aryl, ~~$(CH_2)_m$ aryl$C_{1-12}$ alkyl, $(CH_2)_m$ aryl$C_{2-12}$ alkenyl, $(CH_2)_m$ aryl$C_{2-12}$ alkynyl~~ and $–(CH_2)_m$ heterocyclyl, where m is 0 or 1; ~~and when $R_2$ is $CH_2R_3$ or $C(Y)R_3$, $R_3$ is further selected from S $R_5$ and O $R_5$; m is 0-6; $R_4$ is hydrogen or $C_{1-6}$ alkyl; $R_5$ is $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, $C_{3-7}$ cycloalkyl, $C_{4-7}$ cycloalkenyl, benzyl, aryl or heterocyclyl; w is 0, 1 or 2;~~ and the ~~alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,~~ aryl and heterocyclyl groups are optionally

substituted; and

X is ~~and Y are independently selected from~~ O, ~~S and $NR_6$, where $R_6$ is independently selected from hydrogen, lower alkyl, hydroxy and lower alkoxy~~.

39-40. (Cancelled).

41. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein ring A is optionally substituted with one or more substituents independently selected from halo, $-NH_2$, $-NO_2$, $C_{1-6}$ alkyl, aryl and heterocyclyl, where the aryl and heterocyclyl groups are optionally substituted with halo, $C_{1-6}$ alkyl or halo substituted $C_{1-6}$ alkyl, and the optional substituents are also an N-oxide of the pyridyl ring nitrogen.

42. (Previous Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein ring A is optionally substituted with a substituent selected from halo, alkyl, $C_6H_5-$, $CH_3-C_6H_4-$, $CF_3-C_6H_4-$, pyridyl and $-NO_2$, and the optional substituent is also an N-oxide form of the pyridyl ring nitrogen.

43. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein ring A is not substituted.

44. (Currently Amended) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_2$ is $-C(O)R_3$ ~~selected from $CH_2R_3$, $C(Y)R_3$, $C(Y)OR_3$, $C(Y)N(R_4)R_3$, $C(Y)CH_2N(R_4)R_3$, $C(Y)CH_2SR_3$ and $S(O)_wR_5$~~, where $R_3$ is selected from ~~$(CH_2)_mC_{3-7}$ cycloalkyl, $(CH_2)_mC_{4-7}$ cycloalkenyl,~~ $(CH_2)_m$ aryl~~, $(CH_2)_m$ aryl$C_{1-12}$ alkyl, $(CH_2)_m$ aryl$C_{2-12}$ alkenyl, $(CH_2)_m$ aryl$C_{2-12}$ alkynyl~~ and $-(CH_2)_m$ heterocyclyl, ~~and when $R_2$ is $CH_2R_3$ or $C(Y)R_3$, $R_3$ is further selected from $S-R_5$ and $O-R_5$; m is 0-6, $R_4$ is hydrogen or $C_{1-6}$ alkyl, $R_5$ is selected from $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, $C_{3-7}$ cycloalkyl, $C_{4-7}$ cycloalkenyl, benzyl, aryl and heterocyclyl; w is 0, 1 or 2,~~ and the ~~alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,~~ aryl and heterocyclyl groups are optionally substituted with one or more substituents selected from $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, halo, halo–$C_{1-6}$ alkyl, $CF_3$, hydroxy, mercapto, nitro, cyano, $NH_2$, mono and di($C_{1-6}$ alkyl) amino, phenyl, benzyl and heterocyclyl, the substituents being optionally substituted.

45. (Cancelled).

46. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_2$ is $-COR_3$, and $R_3$ is optionally substituted aryl or optionally substituted heterocyclyl.

47. (Previously Presented) The compound according to claim 46, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_3$ is optionally substituted and is selected from phenyl, naphthyl, furyl, thienyl, pyrrolyl, *H*-pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, triazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, tetrazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyranyl, pyrazinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, triazinyl, 1*H*-thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, uridinyl, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzotriazinyl, naphthyridinyl and pteridinyl.

48. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_3$ is optionally substituted with one or more substituents selected from $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, halo, halo–$C_{1-6}$ alkyl, $CF_3$, hydroxy, mercapto, nitro, cyano, $NH_2$, mono and di($C_{1-6}$ alkyl) amino, phenyl, benzyl and heterocyclyl, where the phenyl, benzyl and heterocyclyl groups are optionally substituted.

49-52. (Cancelled).

53. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein the linker –B–C– is not substituted.

54-56. (Cancelled)

57. (Currently Amended) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_1$ represents phenyl, ~~thienyl, pyrrolyl, pyridyl or $C_{1-6}$ alkylphenyl, each~~ optionally substituted with halo, hydroxy, nitro, –NR'R", $C_{1-12}$ alkyl, phenyl or –O–$R_a$, where R' and R" are independently selected from hydrogen, lower alkyl and –C(O)R, where R is $C_{1-6}$ alkyl, phenyl or heterocyclyl; $R_a$ is –$C_{1-12}$ alkyl, –$C_{3-7}$ cycloalkyl, –$C_{1-12}$ alkyl$C_{3-7}$ cycloalkyl, phenyl or –$C_{1-12}$ alkylphenyl; and the $C_{1-12}$ alkyl, phenyl or $R_a$ group

is optionally substituted with halo, –CN, $–NR^{10}R^{11}$, $–CO_2R^{12}$ or $–CONR^{10}R^{11}$, where $R^{10}$, $R^{11}$ and $R^{12}$ are independently selected from hydrogen and lower alkyl.

58. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_1$ is phenyl optionally substituted with a substituent selected from halo, $–C_{1-6}$ alkyl, $–C_{1-6}$ alkylhalo, $–C_{1-6}$ alkylCN, $–OC_{1-6}$ alkyl, $–OC_{1-6}$ alkylhalo, $–OC_{1-6}$ alkyl$CO_2NH_2$, $–OC_{1-6}$ alkylCN, $–OC_{1-6}$ alkyl$C_{3-7}$ cycloalkyl, $–OC_{1-6}$ alkyl$C_6H_5$, $–OC_{1-6}$ alkyl$OCH_3$, $–OC_6H_5$, $–OC_6H_4$halo, $–CF_3$, $–OCF_3$, –NR'R", $–CO_2H$, $–CO_2C_{1-6}$ alkyl, $–NO_2$, –OH, $–C_6H_5$, $–C_6H_4C_{1-6}$ alkyl, $–C_6H_4$halo and $–OC(O)C_{1-6}$ alkyl; where R' and R" are independently selected from hydrogen, $–C(O)C_{1-6}$ alkyl, $–C(O)C_6H_5$, $–C(O)CH=CHCO_2H$, $–C(O)C_{1-6}$ alkyl$CO_2H$, $–C(O)C_{1-6}$ alkyl$CO_2CH_3$, $–C(O)C_{1-6}$ alkyl$C_6H_5$, $–C(O)C_{1-6}$ alkyl$C_6H_4CH_3$, $–C(O)C_{1-6}$ alkyl$C_6H_4OCH_3$ and $–C(O)C_{1-6}$ alkyl$C_6H_4$halo.

59. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_1$ is halo-phenyl.

60. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_1$ is 4-chlorophenyl.

61. (Cancelled).

62. (Currently Amended) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_2$ is $–C(O)–R_3$ and $R_3$ is $–(CH_2)_m$–aryl or $–(CH_2)_m$–heteroaryl, where ~~m is 0 to 6, and~~ the aryl or heteroaryl group is optionally substituted.

63. (Previously Presented) The compound according to claim 38 of the formula IV




Formula IV

or an N-oxide form or pyridinium salt thereof.

64. (Currently Amended) The compound according to claim 63, or an N-oxide form or pyridium salt thereof, wherein $R_2$ is $-C(O)R_3$ and $R_3$ is $-(CH_2)_m$–aryl or $-(CH_2)_m$–heteroaryl, where ~~m is 0 to 6, and~~ the aryl or heteroaryl group is optionally substituted.

65. (Currently Amended) A compound selected from the group consisting of:

9*b*-(4-chloro-phenyl)-1-(4-fluoro-benzoyl)-1,2,3,9*b*-tetrahydroimidazo[1',2':1,5]-pyrrolo[3,4-*b*]pyridin-5-one;

3*a*-(4-chloro-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(4-fluoro-benzoyl)-3*a*-*p*-tolyl-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-[2-(4-methoxy-phenyl)-acetyl]-3*a*-*p*-tolyl-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(2-chloro-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(4-fluoro-benzoyl)-3*a*-(4-trifluoromethyl-phenyl)-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-[2-(4-methoxy-phenyl)-acetyl]-3*a*-(4-trifluoromethyl-phenyl)-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-[2-(4-methoxy-phenyl)-acetyl]-3*a*-(4-trifluoromethyl-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-fluoro-benzoyl)-5-oxy-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(4-fluoro-benzoyl)-3*a*-(4-methoxy-phenyl)-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-bromo-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-bromo-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

9*b*-(4-chloro-phenyl)-1-(4-fluoro-benzoyl)-1,2,3,9*b*-tetrahydroimidazo[1',2':1,2]-pyrrolo[3,4-*b*]pyridin-5-one;

3*a*-(4-ethyl-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(6-chloro-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(6-chloro-pyridazine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-bromo-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-bromo-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,6,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

9*b*-(4-chloro-phenyl)-1-(6-fluoro-pyridine-3-carbonyl)-1,2,3,9*b*-tetrahydroimidazo[1',2':1,2]pyrrolo[3,4-*b*]pyridin-5-one;

9*b*-(4-chloro-phenyl)-1-(6-fluoro-pyridine-3-carbonyl)-1,2,3,9*b*-tetrahydroimidazo[1',2':1,5]pyrrolo[3,4-*b*]pyridin-5-one;

3*a*-(4-ethyl-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-ethyl-phenyl)-3-(4-fluoro-benzoyl)-5-oxy-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-ethyl-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-5-oxy-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-ethyl-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(6-phenoxy-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-thiophen-2-yl-thiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4,5,6,7-tetrahydro-benzo[*c*]thiophene-1-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(benzo[*b*]thiophene-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(quinoline-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-pyridin-3-yl-thiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methyl-isoxazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(6-morpholin-4-yl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(1,3-dimethyl-1*H*-thieno[2,3-*c*]pyrazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methyl-2-trifluoromethyl-furan-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methyl-2-phenyl-2*H*-[1,2,3]triazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-phenyl-thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-phenyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[1-(4-fluoro-phenyl)-5-methyl-1*H*-pyrazole-4-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-phenyl-thiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(3,5-dimethyl-isoxazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(1,3,5-trimethyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-methyl-5-phenyl-furan-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-[2-(4-chloro-phenoxy)-pyridine-3-carbonyl]-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-ethylsulfanyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-methylsulfanyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-pentylsulfanyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-phenylsulfanyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-propylsulfanyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-p-tolylsulfanyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-chloro-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-phenoxy-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-bromo-pyridine-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-phenylethynyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-[3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carbonyl]-isonicotinic acid methyl ester;

3*a*-(4-chloro-phenyl)-3-(5-hex-1-ynyl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-thiophen-2-yl-pyridine-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[3-methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-isoxazole-4-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2,5-dimethyl-furan-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(furan-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(furan-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4,5-dimethyl-furan-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-phenylethynyl-furan-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

4-[3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carbonyl]-5-methyl-furan-2-sulfonic acid dimethylamide;

3*a*-(4-chloro-phenyl)-3-[1-(4-chloro-phenyl)-5-methyl-1*H*-pyrazole-4-carbonyl]-1,2,3,3atetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[1-(4-methoxy-phenyl)-5-methyl-1*H*-pyrazole-4-carbonyl]-1,2,3,3atetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2,5-dimethyl-2*H*-pyrazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(1,5-dimethyl-1*H*-pyrazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-ethyl-5-methyl-2*H*-pyrazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-phenyl-2*H*-pyrazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(1-phenyl-5-propyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-*tert*-butyl-2-methyl-2*H*-pyrazole-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(4-bromo-2,5-dimethyl-2*H*-pyrazole-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(4-bromo-2-ethyl-5-methyl-2*H*-pyrazole-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methyl-1-*o*-tolyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methyl-1-phenyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(thiophene-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(thieno[3,2-*b*]thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-pyridin-2-yl-thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-nitro-thiophene-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-nitro-benzo[*b*]thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-chloro-4-methoxy-thiophene-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-bromo-thiophene-2-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-bromo-4-methoxy-thiophene-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methanesulfonyl-thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[5-(2-methyl-thiazol-4-yl)-thiophene-2-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methoxy-thiophene-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(3-chloro-thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(3-chloro-4-methanesulfonyl-thiophene-2-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-methyl-thiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(3-bromo-thiophene-2-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-([2,2']bithiophenyl-5-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(benzo[*b*]thiophene-2-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(isoxazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(3-ethoxy-thiophene-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(3-chloro-4-methyl-thiophene-2-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(3-methyl-5-phenyl-isoxazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

6-[3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carbonyl]-nicotinic acid methyl ester;

3*a*-(4-chloro-phenyl)-3-(6-chloro-pyridine-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-chloro-2-methylsulfanyl-pyrimidine-4-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(pyridine-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-([1,2,3]thiadiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-pyridin-4-yl-thiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-2-pyrazin-2-yl-thiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(benzofuran-2-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(benzo[*c*]isoxazole-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4,5-dichloro-isothiazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[5-(4-methoxy-phenyl)-oxazole-4-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-phenyl-oxazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-isopropyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[3-(4-methoxy-phenyl)-isoxazole-5-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[3-(4-chloro-phenyl)-isoxazole-5-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(1-methyl-3-trifluoromethyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-2-pyridin-2-yl-thiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(2-p-tolyl-thiazole-4-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-2-thiophen-2-yl-thiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(3-phenyl-isoxazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-2-pyridin-3-yl-thiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(2-chloro-5-isopropyl-thiazole-4-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[5-methyl-1-(4-nitro-phenyl)-1*H*-[1,2,4]triazole-3-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[2-(4-methoxy-phenyl)-thiazole-4-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-2-phenyl-thiazole-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-methyl-1*H*-pyrazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[3-(2-chloro-phenyl)-isoxazole-5-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-5-oxy-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(pyrimidine-5-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-5-oxy-3-[2-(1-oxy-pyridin-3-yl)-thiazole-4-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-methyl-furazan-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-isobutyl-isoxazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-isopropyl-2-phenyl-2*H*-pyrazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-furan-2-yl-isoxazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4,5,6,7-tetrahydro-benzo[*d*]isoxazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-pyrazol-1-ylmethyl-furan-2-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-[5-(4-chloro-phenyl)-isoxazole-3-carbonyl]-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(5-phenyl-isoxazole-3-carbonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3-(5-*tert*-butyl-2-phenyl-2*H*-pyrazole-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-fluoro-benzyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-furan-2-ylmethyl-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-pyridin-3-ylmethyl-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carboxylic acid benzylamide;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carboxylic acid phenylamide;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carbothioic acid benzylamide;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]indene-3-carbothioic acid phenylamide; and

3*a*-(4-chloro-phenyl)-3-(toluene-4-sulfonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triaza-cyclopenta[*a*]inden-8-one;

and salts or pharmaceutically acceptable derivatives thereof.

66. (Previously Presented) A pharmaceutical formulation comprising a compound of formula I according to claim 38, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier or excipient.

67-80. (Cancelled).

81. (Previously Presented) The compound according to claim 38 in a substantially pure optically active form.

82-89. (Cancelled).

90. (New) The method according to claim 1, wherein $R_3$ is optionally substituted and is selected from phenyl, furyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, triazolyl, 1,2,3-triazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, pyridyl, pyrimidinyl, and benzothienyl.

91. (New) The compound according to claim 46, or a salt or pharmaceutically acceptable derivative thereof, wherein $R_3$ is optionally substituted and is selected from phenyl, furyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, triazolyl, 1,2,3-triazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, pyridyl, pyrimidinyl, and benzothienyl.